IMTX
Immatics N.V.
9.00
USD
This page is just a preview of the data found in TrendSpider’s full version
Immatics N.V. stock is up 10.02% since 30 days ago. The next earnings date is Mar 19, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 December’s closed higher than November. In the last 4 Unusual Options Trades, there were 1 PUT, 3 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 03 Oct 13:47 | 20 Oct, 2023 | 12.50 | 689 | ||
| 08 Nov 16:21 | 17 Nov, 2023 | 7.50 | 600 | ||
| 08 Nov 16:21 | 17 Nov, 2023 | 7.50 | 600 | ||
| 08 Nov 16:21 | 17 Nov, 2023 | 7.50 | 600 |
Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.
